Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. 2012

Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
Department of Obstetrics and Gynecology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

OBJECTIVE Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are measures of metabolic activity of tumors determined by fluorine-18 fluorodeoxyglucose ([(18)F]FDG) uptake on PET/CT images. The purpose of this study was to investigate the relationship between functional tumor parameters (MTV and TLG) and clinical outcomes in patients with epithelial ovarian cancer (EOC). METHODS Fifty-five patients with EOC who had undergone [(18)F]FDG PET/CT before surgical staging were included in this retrospectively study. For each patient, we determined the highest (SUV(max) and SUV(avg)), the cumulative TLG, and the sum of all MTV, and compared their predictive value of recurrence and the effects of pretreatment functional tumor activity on progression-free interval (PFI). RESULTS The median duration of PFI was 11 (range 3-43) months, and 20 patients (36.4%) experienced recurrence. Poor outcome was associated with higher values for both the MTV (P = 0.022, hazard ratio 5.571, 95% confidence interval 1.279-24.272) and the TLG (P = 0.037, hazard ratio 2.967, 95% confidence interval 1.065-8.265). The Kaplan-Meier survival graphs showed a significant difference in PFI between the groups categorized by MTV and TLG, respectively (P = 0.01 for MTV, P = 0.0287 for TLG, log rank test). CONCLUSIONS Pretreatment metabolic parameters such as MTV and TLG showed statistically significant association with recurrence in patients with EOC. These values can be useful quantitative criteria for disease prognostication in patients with EOC before treatment.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002288 Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed) Carcinoma, Colloid,Carcinoma, Mucinous,Adenocarcinomas, Mucinous,Carcinomas, Colloid,Carcinomas, Mucinous,Colloid Carcinoma,Colloid Carcinomas,Mucinous Adenocarcinoma,Mucinous Adenocarcinomas,Mucinous Carcinoma,Mucinous Carcinomas
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006019 Glycolysis A metabolic process that converts GLUCOSE into two molecules of PYRUVIC ACID through a series of enzymatic reactions. Energy generated by this process is conserved in two molecules of ATP. Glycolysis is the universal catabolic pathway for glucose, free glucose, or glucose derived from complex CARBOHYDRATES, such as GLYCOGEN and STARCH. Embden-Meyerhof Pathway,Embden-Meyerhof-Parnas Pathway,Embden Meyerhof Parnas Pathway,Embden Meyerhof Pathway,Embden-Meyerhof Pathways,Pathway, Embden-Meyerhof,Pathway, Embden-Meyerhof-Parnas,Pathways, Embden-Meyerhof
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
June 2014, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
August 2020, Nuclear medicine communications,
Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
April 2017, Clinical nuclear medicine,
Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
June 2018, Nuclear medicine communications,
Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
January 2019, PloS one,
Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
January 2018, Cancer treatment and research communications,
Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
January 2021, Cancer & metabolism,
Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
January 2019, Revista espanola de medicina nuclear e imagen molecular,
Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
July 2013, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Hyun Hoon Chung, and Hyun Woo Kwon, and Keon Wook Kang, and Noh-Hyun Park, and Yong-Sang Song, and June-Key Chung, and Soon-Beom Kang, and Jae Weon Kim
November 2019, Nuclear medicine communications,
Copied contents to your clipboard!